Enhertu® (trastuzumab deruxtecan)

Asset Publisher

Enhertu® (trastuzumab deruxtecan)

L'Agenzia Italiana del Farmaco rende disponibile il report tecnico-scientifico sul medicinale Enhertu® (trastuzumab deruxtecan).

Il report è presente nella sezione "Report tecnico-scientifici per specialità medicinale" raggiungibile dal box “Link correlati”.

Published on: 10 gennaio 2024

Asset Publisher

Site Map

Pricing and reimbursement

Share

Nested Applications

Highlights

30/12/2024 - AIFA President Nisticò: “With the approval of the single role for scientific officers, high-profile professionals who are strategic for the proper functioning of the Agency are secured”

16/12/2024 - AIFA launches crackdown on conflict of interest. But opens the way for free opinions and consultations by high-profile professionals

ALL NEWS

News

27/12/2024

Available the English version of the 2023 National Report on "National report on medicines use in Italy"

24/12/2024

Hepatitis C: update of 23 December 2024 concerning enrolled patients

18/12/2024

Message of the Minister of Health Orazio Schillaci to AIFA

All news

Galleria

Nested Applications

Press

AIFA President Nisticò: “With the approval of the single role for scientific officers, high-profile professionals who are strategic for the proper functioning of the Agency are secured”

Aifa toggle bar Search

Aifa toggle bar Search